<p><em>Regorafenib, an oral tyrosine kinase inhibitor and antineoplastic agent, has been shown to be effective in managing advanced cancers. However, its use is associated with a variety of adverse events. This retrospective chart review study was conducted to determine the safety profile of regorafenib in King Abdullah Medical City. Data from all patients who received regorafenib between December 2021 and May 2020 were collected, including patient demographics, diagnosis, regorafenib starting and escalated doses, reported adverse events, and associated management. The study found that hyperbilirubinemia and fatigue were the most commonly reported adverse events, with half of the patients discontinuing the medication due to adverse events. Hemifacial spasm and bilateral hydronephrosis were found to be new adverse drug reactions not reported in other studies. The dosing strategy of regorafenib has improved in recent years to provide maximum efficacy with the lowest possible side effects. Adherence to treatment is necessary to prevent further drug toxicity. This study emphasizes the importance of appropriate monitoring and instructing healthcare providers to achieve better outcomes and improve the quality of life for patients. The findings can help healthcare providers make informed decisions regarding the use and management of regorafenib, while also highlighting the need for ongoing research to identify and manage the adverse effects associated with this drug</em></p>